Jaksch Frank L.'s most recent trade in Niagen Bioscience Inc. was a trade of 20,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Niagen Bioscience Inc. | Frank L. Jaksch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share. | 13 Dec 2024 | 50,001 | 281,340 (0%) | 0% | 3.7 | 183,004 | Common Stock |
| Niagen Bioscience Inc. | Jaksch Frank L. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2024 | 50,001 | 0 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director | Sale of securities on an exchange or to another person at price $ 6.19 per share. | 13 Dec 2024 | 37,161 | 244,179 (0%) | 0% | 6.2 | 229,956 | Common Stock |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director | Purchase of securities on an exchange or from another person at price $ 1.69 per share. | 12 Jun 2023 | 7,000 | 231,339 (0%) | 0% | 1.7 | 11,830 | Common Stock |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director, EXECUTIVE CHAIRMAN OF BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2022 | 107,805 | 107,805 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director, EXECUTIVE CHAIRMAN OF BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 25,072 | 25,072 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director, EXECUTIVE CHAIRMAN OF BOARD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2020 | 41,667 | 0 | - | - | Employee Stock Options (right to buy) | |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director, EXECUTIVE CHAIRMAN OF BOARD | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.62 per share. | 10 Dec 2020 | 41,667 | 262,168 (0%) | 0% | 4.6 | 192,502 | Common Stock |
| Niagen Bioscience Inc. | Frank L. Jaksch | Director, EXECUTIVE CHAIRMAN OF BOARD | Sale of securities on an exchange or to another person at price $ 5.19 per share. | 10 Dec 2020 | 37,829 | 224,339 (0%) | 0% | 5.2 | 196,333 | Common Stock |